FindTrial
Sign In

Populational pharmacokinetics of methylphenidate hydrochloride extended-release tablets in Chinese school-age children with attention-deficit/hyperactivity disorder

A Clinical Study of Methylphenidate Hydrochloride and Atomoxetine Hydrochloride in School-Aged Children with ADHD Based on Quantitative Pharmacology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115500
Enrollment
Unknown
Registered
2025-12-26
Start date
2022-04-28
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit Hyperactivity Disorder(ADHD)

Interventions

18 mg/d group:None
36 mg/d group:None

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 11 Years

Inclusion criteria

Inclusion criteria: Han Chinese children aged 6–12 years diagnosed with ADHD, who had been treated with methylphenidate hydrochloride extended-release tablets for more than one month and achieved steady-state plasma concentration.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to the medication or those who experienced severe cardiovascular adverse reactions; 2. Children with other chronic disorders assessed as unsuitable for the medication; 3. The children must have no history of substance abuse, severe developmental disorders, or emotional/psychiatric disorders.

Design outcomes

Primary

MeasureTime frame
Plasma concentration of Methylphenidate ;—

Countries

China

Contacts

Public ContactLi Chen

Children’s Hospital of Chongqing Medical University

chenli2012@126.com+86 23 6837 0551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026